Fibrinogen Concentrate (Human)
Medically reviewed on September 10, 2018
(fi BRIN o gin KON suhn trate HYU man)
- Coagulation Factor I
Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Injection, powder for reconstitution:
Fibryga: ~1 g [exact potency labeled on vial]
RiaSTAP: 900-1300 mg [contains albumin (human); exact potency labeled on vial]
Brand Names: U.S.
- Blood Product Derivative
Fibrinogen (coagulation factor I), a protein found in normal plasma, is required to clot blood. Fibrinogen concentrate made from pooled human plasma replaces this protein which is missing or reduced in patients with a congenital fibrinogen deficiency.
Vd: Fibryga: 70.2 ± 29.9 mL/kg (range: 36.9 to 149.1 mL/kg); RiaSTAP: 52.7 ± 7.48 mL/kg (range: 36.22 to 67.67 mL/kg)
Clearance faster in pediatric patients <16 years than adults
Biological fibrinogen: 100 hours (Kamath 2003)
Pediatric patients <16 years: Initial data suggests decreased compared to adults (Manco-Johnson 2009): 69.9 ± 8.5 hours (RiaSTAP)
Adults: Fibryga: 75.9 ± 23.8 (40 to 157 hours); RiaSTAP: 78.7 ± 18.13 hours (range: 55.73 to 117.26 hours)
Use: Labeled Indications
Congenital fibrinogen deficiency: Treatment of acute bleeding episodes in patients with congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogenemia.
Severe, immediate hypersensitivity reactions, including anaphylaxis to fibrinogen, human plasma-derived products, or any component of the formulation.
Congenital fibrinogen deficiency: IV: Note: Maintain a target fibrinogen level of 100 mg/dL for minor bleeding and 150 mg/dL for major bleeding.
When baseline fibrinogen level is known:
Fibryga: Dose (mg/kg) = [Target level (mg/dL) - measured level (mg/dL)] divided by 1.8 (mg/dL per mg/kg body weight)
RiaSTAP: Dose (mg/kg) = [Target level (mg/dL) - measured level (mg/dL)] divided by 1.7 (mg/dL per mg/kg body weight)
When baseline fibrinogen level is not known: 70 mg/kg
Refer to adult dosing.
Congenital fibrinogen deficiency: IV:
Fibryga: Children ≥12 years and Adolescents: Refer to adult dosing.
RiaSTAP: Children ≥8 years and Adolescents: Refer to adult dosing.
Dosing: Renal Impairment
There are no dosage adjustments provided in the manufacturer's labeling.
Dosing: Hepatic Impairment
There are no dosage adjustments provided in the manufacturer's labeling.
Fibryga: Prior to reconstitution, warm both powder and sterile water for injection to room temperature; if water bath is used for warming, the water bath should not exceed 37°C (98°F). Reconstitute with 50 mL of SWFI; gently swirl until dissolved (~5 to 10 minutes), do not shake.
RiaSTAP: Transfer 50 mL of SWFI into fibrinogen concentrate vial. Gently swirl until dissolved; do not shake.
IV: For IV administration only; infuse at a rate not exceeding 5 mL/minute. Solution should be infused at room temperature. Do not administer with other products or IV solutions. Administration should be completed within 8 hours (RiaSTAP) or 4 hours (Fibryga) after reconstitution.
Store at 2°C to 25°C (36°F to 77°F) in original carton; do not freeze. Protect from light. RiaSTAP is stable for 8 hours after reconstitution when stored at 20°C to 25˚C (68°F to 77°F); Fibryga should be used immediately or within 4 hours after reconstitution, do not refrigerate or freeze. Discard partially used vials.
There are no known significant interactions.
1% to 10%:
Central nervous system: Headache (>1%)
Dermatologic: Erythema (≤8%), pruritus (≤8%)
Gastrointestinal: Vomiting (>5%)
Neuromuscular & skeletal: Weakness (>5%)
Miscellaneous: Fever (>5%)
<1%, postmarketing, and/or case reports: Anaphylaxis, arterial thrombosis, chills, deep vein thrombosis, dyspnea, hypersensitivity reaction, myocardial infarction, nausea, pulmonary embolism, skin rash, thromboembolism
Concerns related to adverse effects:
• Hypersensitivity: Hypersensitivity reactions (eg, hives, generalized urticaria, chest tightness, wheezing, hypotension, anaphylaxis) may occur. In the event of hypersensitivity reactions, treatment should be discontinued immediately.
• Thrombotic events: Thrombosis may occur spontaneously in patients with congenital fibrinogen deficiency with or without fibrinogen replacement therapy. Thromboembolic events have been reported in patients receiving fibrinogen concentrate. Consider potential risk of thrombosis with use; monitor for signs and symptoms of thrombosis.
Dosage form specific issues:
• Human plasma: Product of human plasma; may potentially contain infectious agents which could transmit disease (eg, viruses and theoretically the Creutzfeldt-Jakob disease [CJD]). Screening of donors, as well as testing and/or inactivation or removal of certain viruses, reduces the risk. Infections thought to be transmitted by this product should be reported to the manufacturer.
• Appropriate use: Not indicated for the treatment of dysfibrinogenemia.
Fibrinogen level; signs/symptoms of hypersensitivity and thrombosis
Pregnant patients with congenital fibrinogen deficiency may have an increased risk of bleeding, thrombosis, and pregnancy loss; therefore, close surveillance is recommended. Maternal fibrinogen concentrations increase during pregnancy but do not protect against potential complications. Prophylaxis throughout pregnancy may be needed and higher doses may be required as pregnancy progresses. Replacement therapy may be initiated prior to conception. Plasma derived fibrinogen concentrate may be used for treatment or prevention of bleeding in patients with severe deficiency (RCOG [Pavord 2017]).
• Discuss specific use of drug and side effects with patient as it relates to treatment. (HCAHPS: During this hospital stay, were you given any medicine that you had not taken before? Before giving you any new medicine, how often did hospital staff tell you what the medicine was for? How often did hospital staff describe possible side effects in a way you could understand?)
• Have patient report immediately to prescriber signs of severe cerebrovascular disease (change in strength on one side is greater than the other, difficulty speaking or thinking, change in balance, or vision changes), signs of DVT (edema, warmth, numbness, change in color, or pain in the extremities), severe dizziness, passing out, coughing up blood, shortness of breath, angina, loss of strength and energy, diarrhea, jaundice, severe headache, fast breathing, nausea, vomiting, or chills (HCAHPS).
• Educate patient about signs of a significant reaction (eg, wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat). Note: This is not a comprehensive list of all side effects. Patient should consult prescriber for additional questions.
Intended Use and Disclaimer: Should not be printed and given to patients. This information is intended to serve as a concise initial reference for health care professionals to use when discussing medications with a patient. You must ultimately rely on your own discretion, experience, and judgment in diagnosing, treating and advising patients.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
More about fibrinogen
- Fibrinogen Side Effects
- During Pregnancy
- Dosage Information
- Drug Interactions
- En Español
- Drug class: miscellaneous coagulation modifiers
Other brands: RiaSTAP